Know Cancer

forgot password

Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination With Abraxane (Abraxane) in Patients With Metastatic Breast Cancer (MBC) [Phase I and II]

Phase 1/Phase 2
18 Years
Not Enrolling
Metastatic Breast Cancer

Thank you

Trial Information

Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination With Abraxane (Abraxane) in Patients With Metastatic Breast Cancer (MBC) [Phase I and II]

Phase I Objectives

- To determine the Maximum Tolerated Dose (MTD) of the combination of (DOXIL) and
Abraxane in patients with Metastatic Breast Cancer (MBC).

- Determine the dose-limiting toxicity (DLT) of DOXIL and Abraxane.

Phase II Objectives

Primary Objective

- To determine the response rate of DOXIL and Abraxane in patients with MBC.

Secondary Objectives

- To determine the time to disease progression in patients with MBC receiving DOXIL and

- To assess the tolerability of this regimen in women with MBC and assess toxicity

Inclusion Criteria:

- Male or female over the age of 18.

- ECOG performance status 0-2.

- Patients with a biopsy proven or radiologically confirmed metastatic breast cancer.

- Chemotherapy naïve in the metastatic setting or had one prior regimen for metastatic
breast cancer.

- Patients who had multiple non-chemotherapy agents for metastatic breast cancer are
eligible i.e. hormonal therapies, Herceptin, Avastin etc.

- If they had received a taxane or anthracyclines in the adjuvant or metastatic
setting, the interval should be more than 12 month and the cumulative dose of
anthracycline will have to be taken into account (for both adjuvant and metastatic

- Patients who have Her2/neu negative breast cancer.

- No significant co-morbid conditions as determined by the investigator.

- Patients must have normal cardiac function, as evidenced by a left ventricular
ejection fraction (LVEF) within institutional normal limits. A MUGA scan or
echocardiogram (the same test must be used throughout the study) to evaluate LVEF
must be done within 4 weeks (28 days).

- Normal laboratory values as explained below.

- No active malignancy in the past 5 years (other than non- melanomatous cutaneous
cancer, cervical intraepithelial neoplasia, or in-situ cervical cancer).

- Ability to understand and the willingness to sign a written informed consent

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as
greater than or equal to 20 mm with conventional techniques or as greater than or
equal to 10 mm with spiral CT scan. See section for the evaluation of measurable
disease. The protocol will employ the RECIST criteria.

- Negative serum or urine pregnancy test at screening for patients of child-bearing

- Patients with reproductive potential must use an adequate contraceptive method (e.g.,
abstinence, intrauterine device, oral contraceptives, barrier device with spermicide
or surgical sterilization) during treatment and for three months after completing

Exclusion Criteria:

- Pregnant or breast-feeding.

- Patients with CNS metastatic disease can be excluded if it is diffuse involvement or
CSF spread or metastasis not amenable to gamma knife surgery or neurosurgical
intervention (Following neurosurgical removal of solitary or up to 3 metastasis or
following gamma-knife procedure for up to 3 metastasis, patient can become eligible).
For those patients with stable CNS metastasis for more than 12 months will be
eligible for study.

- Evidence of significant co-morbid conditions or end organ dysfunction.

- Patients with Grade 3 or 4 neuropathy at baseline evaluation from any cause will also
be excluded.

- Patients are permitted to receive radiation therapy (palliative or primary), but
their study drugs will be held during the course of radiation therapy until
hematopoietic recovery. The irradiated sites will not be used for response in the
Phase II setting.

- Prior anthracycline dose exceeding 360 mg/m2 for doxorubicin (including Doxil) or 720
mg/m2 for epirubicin will make them ineligible.

- History of hypersensitivity reactions attributed to a conventional formulation of
doxorubicin HCL or the components of DOXIL. Prior history of severe reaction to Taxol
will also make them ineligible.

- Myocardial infarct within 6 months before enrollment, New York Heart Association
(NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, clinically significant pericardial disease, or
electrocardiographic evidence of acute ischemic or active conduction system

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

This trial will use DOXIL and Abraxane as first or second line chemotherapy in patients with a diagnosis of Metastatic Breast Cancer (MBC).

Outcome Time Frame:

Patients will be restaged every 3 cycles or approximately every 9 weeks. At the time of restaging, patients will have their disease status classified as complete response (CR), partial response (PR), progressive disease (PD) or stable disease (SD)

Safety Issue:


Principal Investigator

Jame Abraham, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

West Virginia University


United States: Institutional Review Board

Study ID:




Start Date:

February 2007

Completion Date:

October 2008

Related Keywords:

  • Metastatic Breast Cancer
  • breast cancer
  • advanced breast cancer
  • Breast Neoplasms



Clinical Trials Research Unit, West Virginia University Morgantown, West Virginia  26506-9260